Alexion Pharmaceuticals, Inc. (subsidiary of AstraZeneca)

Subsidiary of AstraZeneca (AZN)

Assets

(3 total)
3Total Assets
2Approved
0Phase 3 / Filed
1Phase 1–2 / Early
5Diseases
Quick filter:
Showing 3 of 3 assets
Target & Modality
Acoramidis(Attruby)
Approved
Transthyretin (TTR)Small molecule
Transthyretin-Mediated Amyloidosis
Transthyretin Amyloidosis with Cardiomyopathy
Eculizumab(Soliris)
Approved
Complement C5Monoclonal antibody
Myasthenia GravisThrombotic MicroangiopathyParoxysmal Nocturnal Hemoglobinuria
Generalized Myasthenia Gravis
Phase 2
—
ANCA-Associated Vasculitis

Upcoming events

(6 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
Eculizumab · SolirisPhase 3NMOSD, Neuromyelitis Optica Spectrum Disorders
Est. primary completion 2026-12-07 · NCT06724809 · CT.gov ↗
What to watch
2027 (2)
May 2027 (1)
Eculizumab · SolirisPhase 3Paroxysmal Nocturnal Hemoglobinuria, PNH, Extravascular Hemolysis
Est. primary completion 2027-05-28 · NCT06449001 · CT.gov ↗
What to watch
October 2027 (1)
ALXN1820Phase 2Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Est. primary completion 2027-10-11 · NCT07160608 · CT.gov ↗
What to watch
2028 (1)
April 2028 (1)
Acoramidis · AttrubyPhase 3Amyloid Cardiomyopathy, Transthyretin-Related
Est. primary completion 2028-04-15 · NCT04988386 · CT.gov ↗
What to watch
2031 (1)
October 2031 (1)
Acoramidis · AttrubyPhase 3Amyloidosis, Amyloid Cardiomyopathy, Transthyretin Amyloidosis, Cardiomyopathies, Heart Diseases, Polyneuropathies
Est. primary completion 2031-10 · NCT06563895 · CT.gov ↗
What to watch
2037 (1)
November 2037 (1)
Acoramidis · AttrubyPhase 3Amyloidosis in Transthyretin (TTR), Amyloidosis, Familial, Amyloid Cardiomyopathy, Amyloid Cardiomyopathy, Transthyretin-Related …
Est. primary completion 2037-11 · NCT07116473 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

No financial reports recorded.